Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Valued Over $1B Pulse: Compass Pathways Partners With Radial to Shape Psilocybin Care Delivery Pulse: Bial Launches KYNMOBI in the UK for Parkinson’s OFF Episodes Pulse: NeuraLight Completes Landmark Parkinson’s Biomarker Trial Pulse: EA Pharma Initiates Phase 3 Evenamide Trial in Schizophrenia Pulse: Rapport Therapeutics … Read more
Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD.
In today’s NeuroPulse Daily, the neurology sector moves forward across regulatory acceleration, digital behavioural health validation, pivotal ALS trial expansion, and spine care reimbursement gains.
Today’s neurology landscape delivered major moves across digital therapeutics, gene therapy, neuroimmune modulation, and regenerative medicine, signaling a decisive shift toward clinically validated, translationally focused innovation.
Satellos advances a Phase 2 pediatric DMD trial; Rapid completes DISTALS stroke study; lecanemab gains commercial-insurance access in China; ALS and AD platforms progress.
A high-momentum day across neuroscience as fresh investment, mechanistic innovation, and late-stage readouts tighten the path from discovery to impact.
The neurology sector moved on several fronts today, with developments spanning Alzheimer’s diagnostics, mitochondrial-targeted drug programs, neuromodulation evidence standards, glioblastoma immunotherapy, spine portfolio restructuring, and new work on surrogate markers in neurodegeneration. Taken together, the updates reflect a field shifting toward earlier disease interception, biomarker-driven precision, and evidence packages that anticipate payer scrutiny. Alzheimer’s continues … Read more
AI Imaging Advances, ALS Pipeline Progress, and New CMS Reimbursement Gains Signal Steady Momentum in a Holiday-Quiet Neurology Cycle Even as Thanksgiving week typically slows the flow of biotech and medtech announcements, the neurology sector delivered a trio of meaningful developments across imaging innovation, neurodegenerative drug progress, and federal reimbursement policy. Together, they reflect a … Read more
This edition of Synopulse’s NeuroPulse tracks major CMS reimbursement boosts, pivotal ALS and SMA milestones, robotic and AI-powered medtech breakthroughs, and new biomarker and neurodevelopment updates shaping tomorrow’s neurology landscape.
Today’s Synopulse NeuroPulse Daily Summary highlights major shifts in neurology, from CMS reimbursement stability and pivotal trial clearances to new medtech platforms and key financing rounds, capturing the most critical regulatory, clinical, and innovation-driven movements shaping the field.